oncgnostics GmbH, a Jena, Germany-based molecular diagnostics company, closed a seven-digit Euro Series A financing round.
The round was led by bm|t beteiligungsmanagement thüringen GmbH, with participation from Sparkasse Jena-Saale-Holzland and Anastasia Zepik and existing investors High-tech Gruenderfonds (HTGF) and Stiftung fuer Technologie, Innovation und Forschung Thueringen (STIFT).
The company intends to use the funds for CE mark and market entry of its cervical cancer diagnostics test GynTect®
Spun out from the University women’s Hospital Jena, and led by Dr. Alfred Hansel, CEO, and Dr. Martina Schmitz, CSO, oncgnostics focuses on in vitro diagnostic tests for the early and accurate detection of cancer utilizing proprietary epigenetic biomarkers. The initial product developed, GynTect®, allows the rapid and reliable detection of cervical precancerous lesions and cancer.
17/04/2012: oncgnostics Raises Seed Funding